Genprex Inc. (GNPX)

REQORSA Approved For Dose Escalation In Phase 1/2 Trial


Robert LeBoyerMedia Inquiries
Senior Life Sciences Analyst
August 16, 2022
Report ID: 25149
Get Report
Refer to the full report for the price target, fundamental analysis, and rating.

Equity Research provided by Noble Capital Markets is available at no cost to Registered users of Channelchek.

Already Registered? Click the ‘Get Report’ button to login and view the research report.

Not a Member? Click ‘Join’ or ‘Get Report’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.


Genprex Inc.
Genprex Inc.
Healthcare
Biotechnology
Ticker
GNPX
Current Price
$1.3189 3.85%
Market Cap
$63.3M
Price Target
Refer to Report
Volume
75.0K
52wk Range
$1.17 - $3.62
Related Research Reports
8/16/2022

REQORSA Approved For Dose Escalation In Phase 1/2 Trial
REQORSA Approved For Dose Escalation In Phase 1/2 Trial (GNPX)
1/5/2022

Reqorsa Receives Second Fast Track Designation
Reqorsa Receives Second Fast Track Designation (GNPX)
12/14/2021

Reqorsa Could Be The First Systemic Gene Therapy
Reqorsa Could Be The First Systemic Gene Therapy (GNPX)
12/22/2020

REQORSA Manufacturing is Scaled Up for Clinical Testing
REQORSA Manufacturing is Scaled Up for Clinical Testing (GNPX)

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
© 2018-2022 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.